Precigen, Inc. (NASDAQ:PGEN) held its Q4 2024 Earnings Conference Call on March 19, 2025, at 4:30 PM ET.
Representing the company were:
– Steven Harasym from Investor Relations
– Dr. Helen Sabzevari, President and CEO
– Rutul Shah, COO
– Phil Tennant, Chief Commercial Officer
– Harry Thomasian, CFO
Joining the call were:
– Jason Butler from Citizens
– Carolina Ibanez Ventoso from Stifel
– Swayampakula Ramakanth from H.C. Wainwright
– Jennifer Kim from Cantor
– Brian Cheng from JPMorgan
Operator:
Good evening! You’re warmly welcomed to Precigen’s call discussing the full year 2024 financial results along with some business updates. The lines are currently set to listen-only. After our opening remarks, there will be an opportunity for questions. Just a quick reminder, we’re recording today’s event. Steve Harasym from Investor Relations will now take over. Steve?
Steven Harasym:
Thanks, Alan. Hello everyone and thanks for spending your afternoon with us. Today, I’m joined by some integral members of our team: Dr. Helen Sabzevari, our President and CEO; our CFO, Harry Thomasian; Phil Tennant, our Chief Commercial Officer; and Rutul Shah, our COO.
Before diving in, I need to remind you about our forward-looking statements. Our discussion today will include predictions and forward-looking statements. Please be advised that these are based on our current expectations and there are associated risks and uncertainties. These could lead to actual outcomes differing from what we might project today. For details, please take a look at the safe harbor statement in our recent SEC filings, as well as in Precigen’s risk factors.
With those formalities out of the way, I’ll hand things over to Dr. Sabzevari. Helen?
Helen Sabzevari:
Thank you, Steve. And a big thank you to everyone here today. We’re setting the stage for an exciting year-end update for 2024. Precigen is at a pivotal point with the upcoming commercialization of our leading initiatives.
